Confronto

Thymalin vs. Thymosin Beta-4

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

63958-90-7

77591-33-4

Peso molecolare

1000 g/mol

4921 g/mol

Emivita

0.5 h

nessun dato

Sequenza

nessun dato

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Meccanismo d'azione

Thymalin

Thymalin is a complex of multiple polypeptides extracted from bovine or calf thymus. Postulated mechanisms include modulation of T-lymphocyte maturation, influence on interleukin profiles and stimulation of cellular immune response. Being a multi-component preparation, individual mechanisms are difficult to disentangle. Khavinson and colleagues from St Petersburg have described the mechanism over decades in Russian publications.

Thymosin Beta-4

Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.

Base di evidenze

Evidenza più alta

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Thymalin	Thymosin Beta-4
Germania	Non approvato	Non approvato
RU	Su prescrizione	—
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Thymalin and Thymosin Beta-4?: Thymalin is classified as "Guarigione", while Thymosin Beta-4 is classified as "Guarigione". Thymalin: Complex of low-molecular polypeptides extracted from calf thymus. Approved in Russia since the 1970s as an immunomodulator. The exact composition is not standardised like a synthetic single peptide; Western controlled studies are largely absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Thymalin or Thymosin Beta-4?: The highest available evidence level is "Studio sull'uomo" for Thymalin and "Studio sull'uomo" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Thymalin and Thymosin Beta-4 in Germany and the United States?: Germania: Thymalin — Non approvato, Thymosin Beta-4 — Non approvato. Stati Uniti: Thymalin — Non approvato, Thymosin Beta-4 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Thymalin

Thymosin Beta-4

Germania

Non approvato

Su prescrizione

—

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Thymalin and Thymosin Beta-4?

Thymalin is classified as "Guarigione", while Thymosin Beta-4 is classified as "Guarigione". Thymalin: Complex of low-molecular polypeptides extracted from calf thymus. Approved in Russia since the 1970s as an immunomodulator. The exact composition is not standardised like a synthetic single peptide; Western controlled studies are largely absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Thymalin or Thymosin Beta-4?

The highest available evidence level is "Studio sull'uomo" for Thymalin and "Studio sull'uomo" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Thymalin and Thymosin Beta-4 in Germany and the United States?

Germania: Thymalin — Non approvato, Thymosin Beta-4 — Non approvato. Stati Uniti: Thymalin — Non approvato, Thymosin Beta-4 — Non approvato. These are factual summaries with source and review date on the individual pages.